<?xml version='1.0' encoding='utf-8'?>
<document id="27379498"><sentence text="Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors."><entity charOffset="70-80" id="DDI-PubMed.27379498.s1.e0" text="paclitaxel" /></sentence><sentence text="The objective of this phase II study was to evaluate pharmacokinetic interaction potential between ramucirumab and paclitaxel in patients with advanced cancer"><entity charOffset="115-125" id="DDI-PubMed.27379498.s2.e0" text="paclitaxel" /></sentence><sentence text="" /><sentence text="This study was designed to assess 2-way pharmacokinetic drug-drug interactions between ramucirumab and paclitaxel"><entity charOffset="87-98" id="DDI-PubMed.27379498.s4.e0" text="ramucirumab" /><entity charOffset="103-113" id="DDI-PubMed.27379498.s4.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.27379498.s4.e0" e2="DDI-PubMed.27379498.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27379498.s4.e0" e2="DDI-PubMed.27379498.s4.e1" /></sentence><sentence text=" Twenty-four patients participated in Part A, which consisted of a 2-week monotherapy period in which paclitaxel 80 mg/m(2) was administered on day 1, followed by a 4-week cycle of combination treatment with ramucirumab (8 mg/kg on days 1 and 15; paclitaxel on days 1, 8, and 15)"><entity charOffset="102-112" id="DDI-PubMed.27379498.s5.e0" text="paclitaxel" /><entity charOffset="208-219" id="DDI-PubMed.27379498.s5.e1" text="ramucirumab" /><entity charOffset="247-257" id="DDI-PubMed.27379498.s5.e2" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.27379498.s5.e0" e2="DDI-PubMed.27379498.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27379498.s5.e0" e2="DDI-PubMed.27379498.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27379498.s5.e0" e2="DDI-PubMed.27379498.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27379498.s5.e1" e2="DDI-PubMed.27379498.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27379498.s5.e1" e2="DDI-PubMed.27379498.s5.e2" /></sentence><sentence text=" Patients could continue to receive combination therapy with ramucirumab and paclitaxel"><entity charOffset="61-72" id="DDI-PubMed.27379498.s6.e0" text="ramucirumab" /><entity charOffset="77-87" id="DDI-PubMed.27379498.s6.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.27379498.s6.e0" e2="DDI-PubMed.27379498.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27379498.s6.e0" e2="DDI-PubMed.27379498.s6.e1" /></sentence><sentence text=" In 16 patients in Part B, ramucirumab monotherapy was administered on day 1 of a 3-week cycle" /><sentence text=" Patients could continue to receive ramucirumab monotherapy or combination therapy with paclitaxel"><entity charOffset="88-98" id="DDI-PubMed.27379498.s8.e0" text="paclitaxel" /></sentence><sentence text="" /><sentence text="Concomitant administration of ramucirumab had no effect on pharmacokinetics of paclitaxel, with ratios of geometric least squares (LS) means (with ramucirumab vs"><entity charOffset="30-41" id="DDI-PubMed.27379498.s10.e0" text="ramucirumab" /><entity charOffset="79-89" id="DDI-PubMed.27379498.s10.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.27379498.s10.e0" e2="DDI-PubMed.27379498.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27379498.s10.e0" e2="DDI-PubMed.27379498.s10.e1" /></sentence><sentence text=" alone) of 1" /><sentence text="09 (90 % confidence interval [CI] 0" /><sentence text="93, 1" /><sentence text="29) for AUC(0-∞) and 0" /><sentence text="97 (90 % CI 0" /><sentence text="83, 1" /><sentence text="13) for C max" /><sentence text=" In addition, similar ramucirumab pharmacokinetic characteristics were observed with or without paclitaxel administration"><entity charOffset="96-106" id="DDI-PubMed.27379498.s18.e0" text="paclitaxel" /></sentence><sentence text=" The ratios of geometric LS means of AUC(0-∞) and C max of ramucirumab (with paclitaxel vs"><entity charOffset="59-70" id="DDI-PubMed.27379498.s19.e0" text="ramucirumab" /><entity charOffset="77-87" id="DDI-PubMed.27379498.s19.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.27379498.s19.e0" e2="DDI-PubMed.27379498.s19.e0" /><pair ddi="false" e1="DDI-PubMed.27379498.s19.e0" e2="DDI-PubMed.27379498.s19.e1" /></sentence><sentence text=" alone) were 1" /><sentence text="00 (90 % CI 0" /><sentence text="84, 1" /><sentence text="19) for AUC(0-∞) and 1" /><sentence text="07 (90 % CI 0" /><sentence text="93, 1" /><sentence text="24) for C max, respectively" /><sentence text="" /><sentence text="Concomitant paclitaxel administration is unlikely to affect the pharmacokinetics of ramucirumab, and vice versa"><entity charOffset="12-22" id="DDI-PubMed.27379498.s28.e0" text="paclitaxel" /><entity charOffset="84-95" id="DDI-PubMed.27379498.s28.e1" text="ramucirumab" /><pair ddi="false" e1="DDI-PubMed.27379498.s28.e0" e2="DDI-PubMed.27379498.s28.e0" /><pair ddi="false" e1="DDI-PubMed.27379498.s28.e0" e2="DDI-PubMed.27379498.s28.e1" /></sentence><sentence text=" The incidence and severity of adverse events were consistent with the known safety profiles of paclitaxel and ramucirumab"><entity charOffset="96-106" id="DDI-PubMed.27379498.s29.e0" text="paclitaxel" /><entity charOffset="111-122" id="DDI-PubMed.27379498.s29.e1" text="ramucirumab" /><pair ddi="false" e1="DDI-PubMed.27379498.s29.e0" e2="DDI-PubMed.27379498.s29.e0" /><pair ddi="false" e1="DDI-PubMed.27379498.s29.e0" e2="DDI-PubMed.27379498.s29.e1" /></sentence><sentence text="" /></document>